Evidence map›Paper›PMID 41231417›Full record

ArticleDigestive diseases and sciences2026

S100A6 Regulated by PATZ1 Promotes Liver Fibrosis by Activating Hepatic Stellate Cells.

Qian Xue, Fengling Peng, Chunhong Guo, Youping Zhou, Li Zhong, Lu Huang, Shan Li, Liang Deng, Jinqiu Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qian XueDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fengling PengDepartment of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chunhong GuoDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Youping ZhouDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li ZhongDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Lu HuangChongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China.
Shan LiDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Liang DengDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. dengliang@cqmu.edu.cn.
Jinqiu ZhaoDepartment of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

Jinqiu Zhao No.82100656,2022M710563,cstc2020jcyj-msxmX0045Liang Deng No.82070626,2020FYYX008,KJQN202200405,XKTS102Qian Xue No.cstc2021jcyj-msxmX0092
6 · The paper itself

Abstract

backgroundThe transition of hepatic stellate cells (HSCs) from a quiescent state to active myofibroblasts plays a pivotal role in the progression of hepatic fibrosis. While S100A6, a member of the S100 protein family, and PATZ1, a transcriptional regulator, are speculated to play crucial roles in the fibrotic process, their specific functions and interactions in the liver fibrosis remain incompletely understood.

methodsC57BL/6 mice were administrated with CCl

resultsAnalysis of data from the GEO database revealed that PATZ1 expression was significantly decreased in liver cirrhosis patients, negatively correlated with the severity of fibrosis. Overexpression of PATZ1 could inhibit HSCs activation and alleviate liver fibrosis in vivo, as evidenced by downregulated fibrotic markers and decreased fibrotic areas in mice with hepatic fibrosis. Conversely, S100A6 expression was progressively upregulated during liver fibrosis progression, particularly in activated HSCs. Knockdown of S100A6 inhibited HSCs activation and alleviated liver fibrosis both in vitro and in vivo. Mechanistically, RNA-seq analysis suggested PATZ1 negatively regulated S100A6 expression in the activation process of HSCs, and EMSA further confirmed that PATZ1 could binding to the promoter of S100A6 gene.

conclusionS100A6 acted as a downstream target of PATZ1 during HSC activation, and PATZ1 could inhibit HSCs activation through suppression the expression of S100A6. PATZ1/S100A6 offered a potential therapeutic target for the therapy of liver fibrosis.

Indexed as

Hepatic Stellate CellsLiver CirrhosisRepressor ProteinsS100 Calcium Binding Protein A6AnimalsCarbon TetrachlorideHumansMaleMiceMice, Inbred C57BLCarbon TetrachlorideRepressor ProteinsS100 Calcium Binding Protein A6HSCs activationLiver fibrosisPATZ1S100A6α-SMA

Identifiers

PMID41231417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.